| 主权项 |
1. A chemical entity of Formula I: wherein: Y and Z are each independently —CH— or —N—, with the proviso that at least one Y or Z member is —N—; M is 0-5; R1 is each independently selected from H, halo, —CN, —C1-6alkyl, —C1-6alkynyl —C1-6haloalkyl, —C1-6thioalkyl, —C1-6thiohaloalkyl, —C1-6alkoxy, —C1-6haloalkoxy, —SO2C1-6alkyl, aryl, pyrazole, and 2-oxopyrrolidine; or two R1 members are on adjacent carbons and taken together with the carbons to which they are attached form a 5-6 member saturated or unsaturated monocylic ring system comprising one or more oxygen or nitrogen atoms, wherein the ring system is optionally substituted with one or more groups selected from halo, —C1-6alkyl, —C1-6alkoxy, and —C1-C6haloalkoxy; R3 and R4 are each independently selected from the group consisting of H, halo, —CN, —OH, —C1-6alkyl, —C1-6haloalkyl, —C1-6alkenyl, —CH2O-aryl, —C1-6alkoxy, —C1-6haloalkoxy, —C(O)CH3, —CH(OH)(CF3), —(CR10R11)0-3NR12R13, aryl, heteroaryl, heterocycloalkyl, wherein each aryl, heteroaryl and heterocycloalkyl is optionally unsubstituted or substituted with a member each independently selected from the group consisting of —CH3 and —OCH3; R10 and R11 are each independently selected from the group consisting of: —H, —F, —C1-6alkyl, —CF3, and —OH; R12 and R13 are each independently selected from the group consisting of —H, —C1-6alkyl, —CO2-benzyl, —C1-6alkyl(aryl), —C1-6alkyl(heterocycloalkyl), optionally unsubstituted or substituted aryl, —C3-6cycloalkyl, heteroaryl, and heterocycloalkyl; or R12 and R13 are taken together with the nitrogen to which they are attached form an optionally substituted heterocycloalkyl; and
wherein the chemical entity is selected from the group consisting of compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I); and pharmaceutically active metabolites of compounds of Formula (I). |
